Copper-replacement treatment for symptomatic Menkes disease: ethical considerations

Area of Science:

• Genetics
• Pediatric Neurology
• Biochemistry

Background:

• Menkes disease is a rare genetic disorder caused by mutations in the ATP7A gene, leading to copper transport defects.
• Classical Menkes disease presents with severe neurological impairment, hypotonia, developmental delay, and characteristic physical features.

Observation:

• A child with classical Menkes disease and a novel ATP7A mutation received subcutaneous copper histidine injections from 15 months of age for 2.5 years.
• The treatment resulted in seizure cessation and improved skin and hair pigmentation.
• Despite treatment, severe developmental delays remained, and the child's condition stabilized after treatment cessation.

Findings:

• Copper histidine therapy can ameliorate some clinical manifestations of Menkes disease, such as seizures and hypopigmentation.
• The treatment did not reverse established severe neurological deficits in this case.
• Ethical dilemmas arise when considering copper treatment for Menkes disease diagnosed after symptom onset, particularly regarding potential benefits, risks, and parental autonomy.

Implications:

• Copper supplementation may be beneficial in Menkes disease, but its efficacy is likely dependent on the timing of initiation relative to symptom onset.
• The case highlights the complex ethical considerations in managing rare pediatric genetic disorders, especially when treatment efficacy is uncertain.
• Further research is needed to establish optimal treatment protocols and ethical guidelines for Menkes disease management.